PATENT CLAIM ANALYSIS

Application Number: 16269871
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["544", "184000"]

Abstract:
The present invention is directed to dihydrochloric acid and dibenzenesulfonic acid salts of the c-Met kinase inhibitor 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and pharmaceutical compositions thereof, useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways. The present invention further relates to processes and intermediates for preparing 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide, and salts thereof.

Claim (Index 22):
The salt of  claim 16 , having a DSC thermogram substantially as shown in  FIG. 5 .

Metadata:
- Claim Count in Document: 8.0
- Percentile: 99.0
- Lexical Diversity: 1.79592
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12469360', '15355630', '13793864', '15969519', '13019718']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8163050671379907
- 35 USC 102 Novelty (BERT): 0.5522307254949992
- Combined Prediction Score: 0.7898976329736915
- Mean Citation Score: 390.673944
- Max Citation Score: 474.64172
- Similarity Product: 291.774071757784

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test